This modest difference in awareness may reflect the more intuitive understanding of SGLT2-inhibitors as glucose-lowering agents in T2DM—due to their mechanism of promoting urinary glucose excretion—versus the more complex and less familiar cardiorenal benefits in heart failure management.19 This evidence concerns the gene SLC5A2 and heart failure.